
Zynteglo (beti-cel) gene therapy – A potential game-changer for bluebird bio
The ICER has backed bluebird bio’s revolutionary Zynteglo therapy for beta thalassaemia as cost-effective in their draft report. Will FDA’s additional back-to-back endorsement of Zynteglo and eli-cel pave the way for bluebird’s recovery, despite multiple misfires and dwindling finances?